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Abstract
Introduction: The smoking epidemic greatly affected mortality levels and trends, especially among 
men in low-mortality countries. The objective of this article was to examine similarities and differences 
between sexes and low-mortality countries in the mortality imprint of the smoking epidemic. This will 
provide important additions to the smoking epidemic model, but also improve our understanding of 
the differential impact of the smoking epidemic, and provide insights into its future impact.
Methods: Using lung-cancer mortality data for 30 European and four North American or Australasian 
countries, smoking-attributable mortality fractions (SAMF) by sex, age (35–99), and year (1950–
2014) were indirectly estimated. The timing and level of the peak in SAMF35-99, estimated using 
weighting and smoothing, were compared.
Results: Among men in all countries except Bulgaria, a clear wave pattern was observed, with 
SAMF35-99 peaking, on average, at 33.4% in 1986. Eastern European men experienced the highest 
(40%) and Swedish men the lowest (16%) peak. Among women, SAMF35-99 peaked, on average, 
at 18.1% in 2007 in the North American/Australasian countries and five Northwestern European 
countries, and increased, on average, to 7.5% in 2014 in the remaining countries (4% in Southern 
and Eastern Europe). The average sex difference in the peak is at least 25.6 years in its timing and 
at most 22.9 percentage points in its level.
Conclusions: Although the progression of smoking-attributable mortality in low-mortality coun-
tries was similar, there are important unexpected sex and country differences in the maximum 
mortality impact of the smoking epidemic driven by cross-country differences in economic, polit-
ical, and emancipatory progress.
Implications: The formal, systematic, and comprehensive analysis of similarities and differences 
between sexes and 34 low-mortality countries in long-term time trends (1950–2014) in smoking-
attributable mortality provided important additions to the Global Burden of Disease study and 
the descriptive smoking epidemic model (Lopez et al.). Despite a general increase followed by 
a decline, the timing of the maximum mortality impact differs more between sexes than previ-
ously anticipated, but less between regions. The maximum mortality impact among men differs 
considerably between countries. The observed substantial diversity warrants country-specific to-
bacco control interventions and increased attention to the current or expected higher smoking-
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Introduction
The smoking epidemic is currently most advanced in low-mortality 
countries, where it continues to have large social and economic ef-
fects, including increased levels of suffering, disease, death and as-
sociated productivity losses, and health care costs.1 The impact of 
smoking on all-cause mortality levels, all-cause mortality trends, and 
differences therein between countries and sexes is well documented 
for low-mortality countries.2–9
As illustrated by the descriptive smoking epidemic model, the 
timing of the smoking epidemic has differed substantially between 
sexes and low-mortality countries.10,11 Among men, smoking was 
taken up first in Anglo-Saxon and Northwestern European countries, 
and an average of 25 years later in Southern and Eastern Europe. 
Women, in general, took up smoking about two decades later than 
men, and their smoking prevalence levels remained lower than the 
high levels observed among men. Specifically, the maximum smoking 
prevalence ranged from 50% to 80% for men and around 35%–45% 
for women. However, all countries and both sexes display a similar 
pattern, whereby smoking-attributable mortality increased and then 
declined about 30–35 years after the initial increase and subsequent 
decline in smoking prevalence. The peak in smoking-attributable 
mortality is expected to occur about 20 years later for women than 
for men, and to reach maximum levels of 20%–25% among women 
and 30%–35% among men. Countries where the smoking epidemic 
started later may be able to introduce effective preventive interven-
tions during an earlier phase of the smoking epidemic, and thus to 
have lower maximum levels of smoking-attributable mortality than 
countries in later phases of the smoking epidemic.
However, the exact timings and levels of the full mortality im-
print of the smoking epidemic are, as yet, unknown. Let alone, dif-
ferences between sexes and low-mortality countries in these timings 
and levels. Numerous studies have examined the progression of the 
smoking epidemic while using either smoking prevalence12–14or lung 
cancer mortality15–19 as the outcome measure. The Global Burden 
of Disease study provides global, regional, and national estimates 
of smoking prevalence, smoking-attributable deaths, and smoking-
attributable disease burden from 1990 onward.20,21 The few existing 
studies on more long-term trends in smoking-attributable mortality 
only included a few low-mortality countries.10,22 None of the earlier-
mentioned studies however performed a formal and systematic ana-
lysis of country- and sex differences in the timing and level of the 
progression of smoking-attributable mortality.
Such a systematic analysis, however, can not only improve our under-
standing of the differences in the mortality impact of the smoking epi-
demic between countries and sexes, but its outcomes could also be used 
to estimate the future impact of the smoking epidemic in low-mortality 
countries. Although the smoking epidemic is most advanced in low-
mortality countries, it is expected to have an important imprint on popu-
lation health for many years to come, particularly among women.22–25
This article systematically examines similarities and differences 
between sexes and 34 low-mortality countries in the mortality im-
print of the smoking epidemic, and particularly in the level and 
timing of the maximum mortality impact.
Data and Methods
Data and Setting
The analysis includes the national populations of 30 European coun-
tries, United States, Canada, Australia, and New Zealand, by sex and 
age (35–99), for the period 1950–2014.
Lung cancer mortality deaths by age (35–39, …. 75–79, 80+), 
country, sex, and calendar year were retrieved from the WHO Mortality 
Database, updated April 11, 2018.26 All-cause mortality deaths and ex-
posure data for the corresponding populations were retrieved from 
HMD, downloaded September 29, 2018.27 When necessary, additional 
lung cancer mortality data were used or additional calculations were 
applied. See Appendix I for the data and years used by country.
The countries were organized into six main groups: North 
American/Australasian countries (Australia, Canada, New Zealand, 
United States), Northern Europe (Denmark, Finland, Norway, 
Sweden), Western Europe (Austria, Belgium, France, Germany 
(west), Iceland, Ireland, Luxembourg, Netherlands, Switzerland, 
United Kingdom), Southern Europe (Greece, Italy, Portugal, Spain), 
Central Europe (Czech Republic, Germany (east), Hungary, Poland, 
Slovakia, Slovenia), and Eastern Europe (Belarus, Bulgaria, Estonia, 
Latvia, Lithuania, Ukraine, Russia).
Smoking-Attributable Mortality Fractions
For each country and year, age (x)- and sex (s)-specific smoking-
attributable mortality fractions (SAMFx,s) were estimated by applying 
a simplified indirect Peto–Lopez method.23,28 The Peto–Lopez method 
indirectly estimates smoking prevalence based on—predominantly—
country-level observed lung cancer mortality rates, and subsequently 
applies the standard epidemiological population-attributable fraction 
formula and Relative Risks (RRs) of dying from smoking to estimate 
smoking-attributable mortality. Whereas the original Peto–Lopez 
method does so by cause of death, the simplified version does so for 
all causes combined. The method takes into account that not all lung 
cancer deaths are attributable to smoking and includes deaths from 
other causes that could be attributed to smoking.
First, the lifetime smoking prevalence (p) by 5-year age groups and 
sex was indirectly estimated based on country-, age- and sex-specific 
lung cancer mortality rates while controlling for lung cancer mor-
tality that is not because of smoking. This was done by comparing 
the country-specific rates with the aggregated age- and sex-specific 
lung cancer rates of smokers and never-smokers (smoothed) in the 
ACS CPS-II study.28 Subsequently, the sex-specific lifetime smoking 
prevalence by single year of age was obtained by Loess smoothing.
Second, the share of all-cause mortality because of smoking 
(SAMF) was calculated by: SAMFx,s = px,s (RRx,s−1)/(px,s (RRx,s−1)+1), 
where px,s reflect the obtained sex-specific estimates of the lifetime 
smoking prevalence by single year of age, and RRx,s reflect the rela-
tive risks of dying from smoking by single year of age and sex. 
RRs by 5-year age groups (35–39, 40–44, …, 80–84, 85+) and sex 
were obtained by dividing the respective all-cause mortality rates 
among CPS-II current smokers by the respective all-cause mortality 
rates among CPS-II never smokers.29 To control for the exposure of 
smokers to other risk factors, the excess risk was reduced by 30%.30 
We obtained the RRs by single year of age by applying a second-
degree polynomial thereby keeping the RRs stable from age 90 on-
ward for men and from age 87 onward for women.
The subsequent Loess smoothing over age of the SAMFx,s led to a 
negligible difference in the overall estimate of the impact of smoking 
on mortality.
Analysis
To determine the year in which the impact of smoking was greatest, 
SAMFs across ages 35–99 (SAMFs) were obtained by weighting the 
SAMFx,s by age-specific death numbers for each sex, year, and country. 
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maximum of this smoothed trend was obtained. This procedure proved 
more accurate than first applying either age-period or age-period-cohort 
models to the data, and then obtaining the maximum from these models.
Smoothing of the SAMFs involved Loess smoothing with—in 
general—span 0.75 and degree 2. To improve the fit, a span of 0.5 
was used for Australian, Canadian, French, and Spanish women; and 
a span of 1.5 for Icelandic men. For Latvia and Lithuania, a span of 
2.0 and degree 1 was used to avoid focusing too much attention on the 
existing fluctuations. Appendix II illustrates that the smoothing we ap-
plied nicely captures the trend over time while ensuring that the year 
in which the maximum is reached is not influenced by fluctuations.
Results
Looking at the trends in smoothed smoking-attributable mortality 
fractions over ages 35–99 (referred to as SAMF from here onward) 
from 1950 to 2014 (Figure 1; Supplementary Figure 1), among men a 
clear wave pattern of an increase followed by a decline in all countries 
except Bulgaria can be observed. Among women, an increase followed 
by a peak and—in most cases—a subsequent decline was observed in 
the four North American/Australasian countries and five Northwestern 
European countries (Denmark, Norway, Iceland, Ireland, United 
Kingdom) (see as well Figure 2); and an upward trend in SAMF was 
observed in most of the remaining countries. For women in Belarus, 
Russia, and Ukraine, SAMF levels have been consistently low, and a 
peak occurred earlier than among men. Among Bulgarian men and 
women, minimal declines in SAMF levels were observed. Because the 
observed maxima in these five instances most likely do not depict the 
actual peak of the smoking epidemic, they were disregarded.
Among men, the peak in SAMF was, on average, reached in 
1986, at 33.4% (Table 1). SAMF peaked early among men in North 
American/Australasian and Northwestern European countries (1980, 
on average) but also in the Czech Republic (1977) (Table 1; Figure 2; 
Supplementary Table 1). In the majority of these countries, men also ex-
perienced high maximum levels (on average, 32% in North American/
Australasian countries and Western European countries and 27% in 
Northern European countries) (see also Figure 3). Men in Central and 
Eastern European (CEE) countries experienced, on average, the highest 
maximum SAMF (39%), albeit at a later point in time (1993). Men 
in Southern European countries experienced, on average, the peak as 
late as men in the Central European countries (1991), and had the 
lowest maximum level (26.1%, on average). Among men, the max-
imum SAMF was highest among men in Russia (44.4%) and Finland 
(41.9%), and was more than 40% in the United Kingdom, Hungary, 
and Estonia, and was lowest in Sweden (16.0%) and Portugal (17.9%), 
followed by in Iceland (18.5%) and Norway (18.8%).
Among women, the maximum SAMF in the North American/
Australasian and Northwestern European countries was, on average, 
reached in 2013, at 18.1%. Women in Denmark had the highest 
peak, at 22.5%, whereas women in Australia had the lowest peak, 
at 12% (Table 1; Figure 3; Supplementary Table 1). In the remaining 
Northwestern European countries in which SAMF is still increasing, the 
average level reached among women in 2014 was around 10%. The ex-
ceptions are women in Hungary and the Netherlands, who reached high 
SAMF levels in 2014 (17.9% and 15.6%, respectively). Among women 
in Southern and Eastern Europe, the SAMF reached values of only 
around 4%. The lowest SAMF levels among women were in Belarus 
(1.6%), followed by Portugal, Lithuania, and Spain (2.3%–2.5%).
The average difference between men and women in the timing of 
the peak was 24.2 years (unweighted average) for the nine countries in 
which the peak has already been reached among women (Table 1). In the 
North American/Australasian countries, this difference was even slightly 
higher, at 25.8 years. Across all countries, the minimum sex difference 
in the timing was 25.6 years. On average, the difference was at least 
36.4 years for the nine remaining Northwestern European countries, at 
least 23 years in Central and Southern Europe, and at least 16.3 years 
in Eastern Europe. Figure 2 clearly depicts this general pattern but also 
shows important exceptions for individual countries, including Iceland 
(15 years’ difference) and the Czech Republic (37 years’ difference).
The maximum level of SAMF was, on average, 11.6 percentage 
points lower among women than among men in the nine countries 
for which the peak among women has already been reached (Table 1; 
Figure 3). The sex difference was greater in the four North American/
Australasian countries than in the two Northern European countries 
Figure 1. Trends over time in the smoothed smoking-attributable mortality fractions (SAMF) over ages 35–99, 4 North American/Australasian countries and 30 
European countries, 1950–2014*, by region and sex. *Or latest available year: Bulgaria (2010), Canada (2011), Greece (2013), New Zealand (2013), Ukraine (2012), 
Russia (2013). North American/Australasian countries  =  Australia, Canada, New Zealand, USA. Northern European countries  =  Denmark, Finland, Norway, 
Sweden. Western European countries = Austria, Belgium, United Kingdom, France, West Germany, Iceland, Ireland, Luxembourg, Netherlands, Switzerland, 
United Kingdom. Southern European countries = Greece, Italy, Portugal, Spain. Central European countries = Czech Republic, East Germany, Hungary, Poland, 
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(14.7 compared to 6.9 percentage points). Across all countries, the 
maximum average sex difference in the SAMF level is 22.9 per-
centage points. The maximum average sex difference was smallest 
in the remaining Northern European countries, at 18.9 percentage 
points; followed by Southern Europe (21.9), Western Europe (24.2), 
Central Europe (27), and Eastern Europe (34.3).
Discussion
Summary of Results
Among men, a clear wave pattern was observed in all 34 low-mortality 
countries except Bulgaria, with SAMF peaking, on average, at 33.4% in 
1986. Among women, SAMF in the four North American/Australasian 
countries and in Denmark, Iceland, Ireland, Norway, and the United 
Kingdom peaked, on average, at 18.1% in 2007—in line with the 
early peak among men in these country groups. Among women in 
the remaining countries, SAMF is increasing, and reached, on average, 
7.5% in 2014. The (maximum) mortality impact was greatest among 
men in most CEE countries (especially Russia, at 44%) and among 
women in Denmark (22.5%) and was smallest among men in Sweden 
(16%) and among women in Southern and Eastern Europe (4% in 
2014). The average observed difference between women and men in 
the year in which the maximum was reached was 24.2 years, with a 
minimum of 25.6 years for all countries. The average observed sex 
difference in the maximum level of SAMF was 11.6 percentage points, 
with a maximum of 22.9 percentage points for all countries.
Comparison to Previous Research
The reported sex-specific estimates of the exact timings and levels of the 
peak in smoking-attributable mortality fractions for European regions and 
individual European and North American/Australasian countries are novel 
in the context of the previous research outlined in the Introduction section.
Table 1. The Average Timing and Level of the Peak in Smoothed Smoking-Attributable Mortality Fractions (SAMF) Over Ages 35–99, 4 
North American/Australasian Countries and 30 European Countries, 1950–2014*, by Region and Sex
(a) Unweighted average of the level of the peak in SAMF (%)
 






reached (in % 
points)





has not yet 
been reached 
(in % points)




Region Men Men# Women Women# Women@ M – W N M – W N M – W N
All countries 33.2 33.4 10.3 18.1 7.5 11.6 9 26.9 25 22.9 34
N. America/Australasia 32.2 32.2 17.5 17.5 NA 14.7 4 NA NA 14.7 4
Northern Europe 26.9 26.9 14.0 17.9 10.0 6.9 2 18.9 2 12.9 4
Western Europe 32.6 32.6 12.4 19.0 9.6 10.7 3 24.2 7 20.1 10
Southern Europe 26.1 26.1 4.2 NA 4.2 NA NA 21.9 4 21.9 4
Central Europe 37.5 37.5 10.5 NA 10.5 NA NA 27.0 6 27.0 6
Eastern Europe 38.2 40.3 3.9 NA 3.9 NA NA 34.3 7 34.3 7
(b) Unweighted average of the year of the peak in SAMF

















men for all 
countries (in 
years)
Region Men Men# Women Women# Women@ W - M N W - M N W - M N
All countries 1986.3 1985.5 2011.9 2006.9 2013.7 24.2 9 26.1 25 25.6 34
N. America/Australasia 1980.0 1980.0 2005.8 2005.8 NA 25.8 4 NA NA 25.8 4
Northern Europe 1980.8 1980.8 2012.8 2011.5 2014.0 24.0 2 40.0 2 32.0 4
Western Europe 1980.0 1980.0 2011.4 2005.3 2014.0 22.3 3 35.3 7 31.4 10
Southern Europe 1990.8 1990.8 2013.8 NA 2013.8 NA NA 23.0 4 23.0 4
Central Europe 1990.8 1990.8 2014.0 NA 2014.0 NA NA 23.2 6 23.2 6
Eastern Europe 1996.7 1994.5 2013.0 NA 2013.0 NA NA 16.3 7 16.3 7
*Or latest available year: Bulgaria (2010), Canada (2011), Greece (2013), New Zealand (2013), Ukraine (2012), Russia (2013).
#Only those countries for which the max has already been reached. For men in all countries except Bulgaria. For women in Australia, Canada, New Zealand, USA, 
Denmark, Norway, Iceland, Ireland, United Kingdom (N = 9).
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The estimates support the more general statements on the timing 
and levels of the peaks for different regions in the smoking epidemic 
model by Lopez et al..11 These estimates show a general (indication 
of) a wave-shaped pattern over time; a clear distinction in the timing 
of the maximum mortality impact between the North American/
Australasian countries and North-western European countries 
on the one hand (early), and the Southern and Eastern European 
countries on the other (late); and the existence of important differ-
ences between sexes in the timing and level of the smoking epidemic.
Important additional observations include smaller differences 
between regions in the timing of the maximum mortality impact; a 
greater maximum mortality impact among men, with considerable 
diversity between countries; and larger sex differences in the timing 
of the maximum mortality impact.
Figure 2. Sex differences in the timing of the peak in the smoothed smoking-attributable mortality fractions (SAMF) over ages 35–99, 4 North American/
Australasian countries and 30 European countries, 1950–2014*. *Or latest available year: Bulgaria (2010), Canada (2011), Greece (2013), New Zealand (2013), 
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The current analysis reveals that, on average, the maximum 
impact was reached in 1980 for the North American/Australasian 
countries and Northwestern European countries, and in 1993 
for the Southern and Eastern European countries. This difference 
is smaller than the 25-year difference obtained in the smoking-
epidemic model—although their comparison also included Latin 
America, where, on average, the smoking epidemic started later than 
in Southern and Eastern Europe.31
The maximum mortality impact of smoking was highest among 
men in Eastern Europe, particularly in Russia, at 44.4%; and among 
women in Denmark, at 22.5%. These findings are in line with the max-
imum smoking-attributable mortality of 20%–25% for women in the 
smoking epidemic model but are considerably higher than the max-
imum of 30%–35% for men.
The reported sex differences in the timing of the maximum mortality 
impact (24 years for the nine countries with a peak among women; a 
Figure 3. Sex differences in the level of the smoothed smoking-attributable mortality fractions (SAMF) over ages 35–99, 4 North American/Australasian countries 
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minimum of 26 years for all countries; 36 years for the remaining nine 
Northwestern European countries) exceed the 20-year difference sug-
gested in the smoking epidemic model.11 At that point in time, it was 
difficult to make such an assumption since the peak for women had not 
yet been reached. The follow-up article in 201210 reported important 
differences for the four countries under study.
The average sex difference in the maximum level of SAMF of 
11.6 percentage points for the nine countries in which a maximum 
for women has already been observed is in line with the suggested 
difference in the smoking epidemic theory of around 10 percentage 
points (30%–35% among men, 20%–25% among women).11 The 
average sex difference for all countries under study is likely to be-
come substantially smaller than the current maximum difference of 
22.9 percentage points because of the projected increase in smoking-
attributable mortality among women in future years.
Clearly important—partly unanticipated—diversity between coun-
tries and sexes in the mortality imprint of the smoking epidemic exists.
Explanation of Observed Results
The observed country differences in the timing of the maximum im-
pact can, above all, be linked to differences in the onset of the smoking 
epidemic resulting from differences in economic development.
The high-income levels in North American/Australasian and 
most Northwestern European countries facilitated the early automa-
tion of the cigarette production process and the uptake of smoking 
by men.11,32,33. As a result, these countries experienced an early onset 
of the smoking epidemic leading to the observed early timing of the 
maximum impact of smoking among men and the observation of a 
maximum impact of smoking among women in these countries only.
Conversely, in Southern and Eastern European countries, where 
the smoking epidemic started later because of delays in economic de-
velopment,32 the maximum impact of smoking occurred later among 
men, and has yet to reach a peak among women.
The observed important country differences in the maximum 
mortality impact among men can be linked, above all, to differences 
in contextual circumstances and in the awareness of the negative 
health consequences of smoking.
The high share of mortality because of smoking in Eastern Europe2,28,30 
has been attributed to the unfavorable economic, political, and health 
conditions in these countries, especially for men.34 The SAMF levels of 
44% in Russia and 40% in Eastern Europe are in line with past smoking 
prevalences of more than 60% and around 50%–55%, respectively.35,36
The high impacts among men in Finland (41.9%), the United 
Kingdom (40.7%), and Belgium (39.8%) can partly be related to the 
early onset of the smoking epidemic in these countries, in a context 
in which knowledge of the negative effects of smoking was not wide-
spread, and the potential for the initiation of effective preventive 
policies was therefore lower.11,32 Indeed, compared to the North 
American/Australasian countries, there was less awareness of the 
health risks of smoking in these countries.32,37
The low maximum mortality impact in Portugal (and Spain) may 
be explained by the late onset of the smoking epidemic and the low 
GDP, which prevented the widespread diffusion of the smoking epi-
demic.32 Among Swedish men, the high prevalence of smokeless to-
bacco (snus) has played an important role.38
The high smoking impact among Danish women can be related 
to their early uptake of smoking, and high historical smoking preva-
lence and smoking-attributable mortality.39 Explanations include the 
broad acceptance in Denmark of smoking among women as a social 
activity, and smoking being a strategy for coping with stress because 
of heavy workloads and deteriorating living conditions at the time.40
The observed important sex differences in the timing and the level 
of the (maximum) mortality impact can be linked to sex differences 
in smoking prevalence about 30–40 years earlier.41 This sex differ-
ential in smoking prevalence can be explained by men, in general, 
being more prone to take up risky behaviors than women.42 As the 
position of women in society changed with the rise in women’s labor 
force participation,43 and as cultural prohibitions against smoking 
among women were challenged during periods of war and (political) 
liberalization,10 women started taking up smoking several decades 
after men.11 Because, by that time, the negative effects of smoking 
on health were much more known, smoking among women never 
reached the enormously high levels observed among men.
The observed important country differences in the sex difference 
in the timing and the level of the (maximum) mortality impact could 
point to country differences in the interaction of socioeconomic, cul-
tural, and material circumstances with emancipatory factors.43
Important to note is that, because the timing of the maximum 
level differs between men and women, in some countries women 
now have similar or higher smoking-attributable mortality fractions 
than men. Supplementary Figure 1 clearly shows that this is cur-
rently the case for Australia, Canada, Denmark, Iceland, Ireland, 
New Zealand, Norway, Sweden, the United Kingdom, and the United 
States; and soon will be the case for a wide range of Northwestern 
European countries. The other European countries are likely to 
follow, with the probable exception of most Eastern European coun-
tries, where SAMF levels among men are highest and SAMF levels 
among women have remained very low in recent years.
Evaluation of Data and Methods
In this article—and in line with most previous research—an indirect 
method for estimating smoking-attributable mortality was used to 
avoid relying on incomplete detailed historical smoking prevalence 
data, to facilitate the use of high-quality cause-of-death information, 
and to capture the effects not only of smoking prevalence, but of 
smoking duration and smoking intensity.44,45 The Global Burden of 
Disease (GBD) study, till last year, also relied—albeit solely for can-
cers and chronic respiratory diseases—on an indirect method.20,21
As an indirect approach, in the current analysis, an adapted sim-
pler version of the Peto–Lopez method is used.23,28 This is because, 
the Peto–Lopez method has been widely used in the field, among 
which in the GBD study.5,20,25 The adapted version requires even 
less information while leading to similar outcomes. More recently, 
a regression-based indirect method has been developed by Preston, 
Glei, and Wilmoth, leading as well to different variants.46,47 Although 
these methods will result in slightly different estimates,22 the timing 
of the peak of the mortality impact will hardly be affected.
Some assumptions underlying the adapted Peto–Lopez method 
are important to consider.
First, the estimates of smoking-attributable mortality rely heavily on 
the RRs of dying from smoking from the ACS-CPSII study in 1982–1988. 
The sex difference in RRs in this study (2.25 for men; 1.72 for women) 
will therefore partly determine the sex difference in smoking-attributable 
mortality. Because the RRs are not country-specific, the country differ-
ences in the mortality impact of smoking are likely underestimated, be-
cause populations differ in their risk of dying from smoking. The use 
of a time-independent RRs could influence the timing of the maximum 
impact of smoking, but the sex and the country differences in the timing 
of the maximum impact of smoking would remain largely unaltered.
Second, country differences in smoking-attributable mortality are 
likely affected by the assumption of the same ratio for each country 
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not because of smoking) and smoking-attributable lung cancer mor-
tality.48 However, especially in CEE countries, lung cancer mortality 
is likely affected to a certain extent by environmental factors, like 
air contamination and exposure to hazardous occupational agents.49
Thus, whereas the observed sex and country differences in the 
timing of the maximum mortality impact of the smoking epidemic 
seem rather robust, the (maximum) SAMF values and their com-
parison across countries are affected by the method used to estimate 
smoking-attributable mortality. Caution is therefore warranted. 
However, the observed differences between countries and sexes in 
smoking-attributable mortality fractions seem largely in line with 
respective differences in smoking prevalence around 1980.13,36,50 
Also, it is important to note that when attempting to study smoking-
attributable mortality over an extended period of time, reliance on 
an indirect estimation method is a necessity.
Conclusions and Implications
The systematic analysis of long-term time trends (1950–2014) in 
smoking-attributable mortality in 34 low-mortality countries re-
vealed clear similarities and differences between sexes and countries 
in the mortality imprint of the smoking epidemic.
The general observed (indications of a) wave pattern in smoking-
attributable mortality, combined with population-specific evidence 
on the current phase in the progression of the epidemic, provide 
clear indications of the future progression of the smoking epidemic. 
Among men, the impact on mortality will further decline, possibly 
at a reduced rate that will start first in North American/Australasian 
and Northwestern European countries. Among women, the max-
imum mortality impact is expected to be reached relatively soon in 
Sweden, the Netherlands, Switzerland, Finland, Austria, Germany, 
Luxembourg, Italy, the Czech Republic, and Hungary; based on 
either a deceleration of the current increase in SAMF or (increas-
ingly) small differences in SAMF levels between men and women. 
Among women in the remaining, mostly CEE countries, SAMF levels 
could continue to rise for another 20  years, given the increasing 
trends in smoking prevalence up to 2005.13,20,36
The observed considerable diversity between countries and sexes, 
driven by country differences in the economic, political, and emancipa-
tory progress, clearly points to the importance of country-specific to-
bacco control interventions. Although lessons can certainly be learned 
from good practice in the forerunner countries, an adjustment to fit 
the specific national context seems appropriate as well. Increased at-
tention for the current or expected higher shares of mortality because 
of smoking among women compared to men is warranted as well.
Supplementary Material
Supplementary data are available at Nicotine and Tobacco Research online.
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Appendix I. Countries included in the analysis 
and their data availability
Country Start year End year Additional data sources
Australia 1950 2014  
Austria 1955 2014  
Belarus 1981 2014  
Belgium 1954 2014  
Bulgaria 1964 2010  
Canada 1950 2011  
Czech Republic 1953 2014 For 1953–1985, lung cancer 
mortality data for the Czech 
Republic were estimated using 
data from WHOSIS on former 
Czechoslovakia.
Denmark 1951 2014  
Estonia 1981 2014  
Finland 1952 2014  
France 1950 2014  
Germany 1970 2014  
Germany, East 1970 2014 For 1970–1972, lung cancer 
deaths were obtained from the 
Archive DahlWitz Hoppegarten. 
For 1991–2014, lung cancer 
mortality data from www.gbe-
bund were used. 
Germany, West 1956 2014 For 1991–2014, lung cancer 
mortality data from www.gbe-
bund were used.
Greece 1981 2013  
Hungary 1955 2014  
Iceland 1951 2014  
Ireland 1950 2014  
Italy 1951 2014  
Latvia 1980 2014  
Lithuania 1981 2014  
Luxembourg 1967 2014  
Netherlands 1950 2014  
New Zealand 1950 2013  
Norway 1951 2014  
Poland 1959 2014  
Portugal 1955 2014 Eurostat data were used to 
obtain lung cancer deaths for 
2004–2006. 
Russia 1980 2013 WHOSIS exposure data instead 
of HMD exposure data were 
used to calculate lung cancer 
mortality rates.
Slovakia 1953 2014 For 1953–1991, data for 
Slovakia were estimated using 
data from WHOSIS on former 
Czechoslovakia. 
Slovenia 1985 2014  
Spain 1951 2014  
Sweden 1951 2014  
Switzerland 1951 2014  
Ukraine 1981 2012  
United 
Kingdom
1950 2014 Eurostat data were used to obtain 
lung cancer deaths for 2004–2006.
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Appendix II. Trends over time in the smoothed smoking-attributable mortality fractions (SAMF) over 
ages 35–99, 4 North American/Australasian countries and 30 European countries, 1950–2014*, by sex 
and country. (a) Men, (b) women. *Or latest available year: Bulgaria (2010), Canada (2011), Greece 
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